Myeloproliferative Neoplasm (MPN) Panel

Purpose: Myeloproliferative neoplasms (MPN) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal disorders arising from hematopoietic stem cells with somatically altered tyrosine kinase signaling. The current WHO classification of these neoplasms is based on various clinical and pathologic characteristics including the presence of the JAK2, CALR, and MPL mutations. Approximately 99% of polycythemia vera and 80-85% of essential thrombocythemia and idiopathic myelofibrosis will harbor a detectable mutation with this assay.
Genes Tested (exons): JAK2 (12 and 14), CALR (9), and MPL (10)
CPT Codes: 81479
Methodology: Next generation sequencing
Turnaround Time: 14 days
Samples tested: Blood, bone marrow, cell suspensions and/or extracted DNA
Forms: 1. PGM Oncology Requisition
2. Medicare Advance Beneficiary Notice